Kanawha Capital Management LLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 1.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 180,777 shares of the biopharmaceutical company’s stock after selling 2,423 shares during the period. Kanawha Capital Management LLC’s holdings in Pfizer were worth $6,454,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of PFE. Shine Investment Advisory Services Inc. bought a new stake in shares of Pfizer during the 2nd quarter valued at $102,000. Mckinley Capital Management LLC Delaware bought a new stake in shares of Pfizer during the 2nd quarter valued at $103,000. D. Scott Neal Inc. grew its position in shares of Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 504 shares during the period. Herndon Capital Management LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at $120,000. Finally, Private Vista LLC grew its position in shares of Pfizer by 2,277.3% during the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 190,933 shares during the period. 69.75% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have recently issued reports on PFE shares. Jefferies Group set a $37.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research report on Monday, September 18th. Nord/LB reissued a “neutral” rating on shares of Pfizer in a research report on Wednesday, December 27th. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. Goldman Sachs Group set a $36.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, November 1st. Finally, BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Friday, December 15th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $38.77.
Pfizer Inc. (NYSE:PFE) opened at $36.71 on Thursday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer Inc. has a one year low of $30.90 and a one year high of $37.35. The firm has a market cap of $218,820.00, a price-to-earnings ratio of 22.52, a P/E/G ratio of 2.42 and a beta of 1.01.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.61 EPS. research analysts expect that Pfizer Inc. will post 2.59 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be paid a $0.34 dividend. The ex-dividend date of this dividend is Thursday, February 1st. This represents a $1.36 annualized dividend and a yield of 3.70%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is presently 78.53%.
Pfizer announced that its Board of Directors has approved a stock repurchase program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.
TRADEMARK VIOLATION NOTICE: “Pfizer Inc. (PFE) Shares Sold by Kanawha Capital Management LLC” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.com-unik.info/2018/01/04/pfizer-inc-pfe-shares-sold-by-kanawha-capital-management-llc.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
What are top analysts saying about Pfizer? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer and related companies.